Yvonne P. Dragan

6.8k total citations
99 papers, 3.2k citations indexed

About

Yvonne P. Dragan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yvonne P. Dragan has authored 99 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 24 papers in Oncology and 24 papers in Cancer Research. Recurrent topics in Yvonne P. Dragan's work include Carcinogens and Genotoxicity Assessment (19 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Glutathione Transferases and Polymorphisms (14 papers). Yvonne P. Dragan is often cited by papers focused on Carcinogens and Genotoxicity Assessment (19 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Glutathione Transferases and Polymorphisms (14 papers). Yvonne P. Dragan collaborates with scholars based in United States, United Kingdom and Japan. Yvonne P. Dragan's co-authors include Henry C. Pitot, Linda M. Sargent, Matthew F. Peters, Clay W. Scott, H. C. Pitot, Laura K. Schnackenberg, Richard D. Beger, V. Craig Jordan, Weida Tong and Ricky D. Holland and has published in prestigious journals such as Nature Medicine, Nature Biotechnology and Hepatology.

In The Last Decade

Yvonne P. Dragan

98 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yvonne P. Dragan United States 33 1.7k 698 494 490 481 99 3.2k
Baitang Ning United States 32 2.1k 1.2× 942 1.3× 550 1.1× 549 1.1× 456 0.9× 97 3.9k
Frank D. Sistare United States 33 1.9k 1.1× 836 1.2× 327 0.7× 281 0.6× 270 0.6× 109 3.9k
Michael Schwarz Germany 34 2.2k 1.3× 852 1.2× 438 0.9× 687 1.4× 272 0.6× 106 3.7k
John H.N. Meerman Netherlands 29 1.2k 0.7× 453 0.6× 421 0.9× 369 0.8× 244 0.5× 92 3.1k
Joost H.M. van Delft Netherlands 33 1.3k 0.8× 1.0k 1.4× 321 0.6× 229 0.5× 221 0.5× 96 2.7k
Makoto Asamoto Japan 33 1.7k 1.0× 805 1.2× 266 0.5× 515 1.1× 343 0.7× 126 3.3k
Michael E. Burczynski United States 30 2.1k 1.3× 942 1.3× 280 0.6× 408 0.8× 358 0.7× 50 4.3k
Katsumi Imaida Japan 41 2.5k 1.5× 1.9k 2.8× 531 1.1× 1.0k 2.1× 423 0.9× 251 6.3k
Fabrice Morel France 32 1.7k 1.0× 430 0.6× 1.2k 2.4× 683 1.4× 209 0.4× 51 3.6k
Roque Bort Spain 24 1.6k 0.9× 681 1.0× 732 1.5× 484 1.0× 262 0.5× 39 3.1k

Countries citing papers authored by Yvonne P. Dragan

Since Specialization
Citations

This map shows the geographic impact of Yvonne P. Dragan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvonne P. Dragan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvonne P. Dragan more than expected).

Fields of papers citing papers by Yvonne P. Dragan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvonne P. Dragan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvonne P. Dragan. The network helps show where Yvonne P. Dragan may publish in the future.

Co-authorship network of co-authors of Yvonne P. Dragan

This figure shows the co-authorship network connecting the top 25 collaborators of Yvonne P. Dragan. A scholar is included among the top collaborators of Yvonne P. Dragan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvonne P. Dragan. Yvonne P. Dragan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shinozawa, Tadahiro, Kazumasa Miyamoto, K. Scott Baker, et al.. (2025). TAK-994 mechanistic investigation into drug-induced liver injury. Toxicological Sciences. 204(2). 143–153. 2 indexed citations
2.
Koido, Masaru, Momoko Ohori, Yasunori Nio, et al.. (2020). Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nature Medicine. 26(10). 1541–1548. 61 indexed citations
3.
Wagoner, Matthew P., Yi Yang, J. Eric McDuffie, et al.. (2017). Evaluation of Temporal Changes in Urine-based Metabolomic and Kidney Injury Markers to Detect Compound Induced Acute Kidney Tubular Toxicity in Beagle Dogs. Current Topics in Medicinal Chemistry. 17(24). 2767–2780. 26 indexed citations
4.
Peters, Matthew F., et al.. (2012). Evaluation of Cellular Impedance Measures of Cardiomyocyte Cultures for Drug Screening Applications. Assay and Drug Development Technologies. 10(6). 525–532. 32 indexed citations
5.
Hong, Huixiao, Roger Perkins, Leming Shi, et al.. (2009). The Accurate Prediction of Protein Family from Amino Acid Sequence by Measuring Features of Sequence Fragments. Journal of Computational Biology. 16(12). 1671–1688. 11 indexed citations
6.
Schnackenberg, Laura K., Richard C. Jones, Sheeno Thyparambil, et al.. (2006). An Integrated Study of Acute Effects of Valproic Acid in the Liver Using Metabonomics, Proteomics, andTranscriptomics Platforms. OMICS A Journal of Integrative Biology. 10(1). 1–14. 41 indexed citations
7.
Guo, Lei, Hong Fang, Jim Collins, et al.. (2006). Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists. BMC Bioinformatics. 7(S2). S18–S18. 60 indexed citations
8.
Harris, Angela J., Joseph G. Shaddock, Robert R. Delongchamp, Yvonne P. Dragan, & Daniel A. Casciano. (2004). Comparison of Basal Gene Expression in Cultured Primary Rat Hepatocytes and Freshly Isolated Rat Hepatocytes. Toxicology Mechanisms and Methods. 14(5). 257–270. 3 indexed citations
9.
10.
Dragan, Yvonne P., Raquel Valdés, Mireia Gómez-Angelats, et al.. (2000). Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology. 32(2). 239–246. 51 indexed citations
11.
Pitot, Henry C., et al.. (2000). Review article: the stages of gastrointestinal carcinogenesis – application of rodent models to human disease. Alimentary Pharmacology & Therapeutics. 14(s1). 153–160. 35 indexed citations
12.
13.
Li, Donghui, et al.. (1999). Dietary oat lipids‐induced novel DNA modifications and suppression of altered hepatic foci formation. Nutrition and Cancer. 33(1). 40–45. 2 indexed citations
14.
Dragan, Yvonne P.. (1998). Effect of Chronic Administration of Mestranol, Tamoxifen, and Toremifene on Hepatic Ploidy in Rats. Toxicological Sciences. 43(2). 129–138. 4 indexed citations
15.
Nuwaysir, Emile F., Yvonne P. Dragan, R. MCCAGUE, et al.. (1998). Structure–Activity Relationships for Triphenylethylene Antiestrogens on Hepatic Phase-I and Phase-II Enzyme Expression. Biochemical Pharmacology. 56(3). 321–327. 7 indexed citations
16.
Xu, Yihua, et al.. (1998). STEREO: A program on a PC-Windows 95 platform for recording and evaluating quantitative stereologic investigations of multistage hepatocarcinogenesis in rodents. Computer Methods and Programs in Biomedicine. 56(1). 49–63. 20 indexed citations
17.
Sargent, Linda M., Yvonne P. Dragan, Yihua Xu, et al.. (1996). Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat.. PubMed. 56(13). 2985–91. 33 indexed citations
18.
Dragan, Yvonne P., et al.. (1992). Criteria, mechanisms, and potency evaluation for tumor promoters: Dioxin as a model. Chemosphere. 25(1-2). 227–230. 1 indexed citations
19.
20.
Dragan, Yvonne P.. (1991). An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fundamental and Applied Toxicology. 16(3). 525–547. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Baitang Ning Breakdown of academic impact, for papers by Frank D. Sistare Breakdown of academic impact, for papers by Michael Schwarz Breakdown of academic impact, for papers by John H.N. Meerman Breakdown of academic impact, for papers by Joost H.M. van Delft Breakdown of academic impact, for papers by Makoto Asamoto Breakdown of academic impact, for papers by Michael E. Burczynski Breakdown of academic impact, for papers by Katsumi Imaida Breakdown of academic impact, for papers by Fabrice Morel Breakdown of academic impact, for papers by Roque Bort
Rankless by CCL
2026